Samaritan Begins Monotherapy Trial of HIV Drug SP01A

Samaritan Pharmaceuticals has officially initiated a Phase II double-blind, placebo-controlled, multidose, monotherapy study in treatment-experience HIV patients.

The 92-patient trial will assess SP01A's safety and effect on viral load in HIV-1 positive individuals, with evidence of increasing viral load despite treatment with other antiretroviral therapy.